Skysis, LLC, a specialized consulting firm that provides in-depth strategic insights and commercial execution to biopharmaceutical companies, has welcomed Chris Duncan to the team.

Duncan brings more than 20 years of industry experience to Skysis, having worked in organizations from big pharma to start-ups, pre-commercial thru post launch, and consulting in commercial and marketing planning & development. His therapeutic experience includes pain, neurology, diabetes, urology, oncology, HCV, and specialty pharma. He has managed projects across the full range of commercial stages from value assessment to launch and life cycle management. He is proficient in forecasting, P&L, budgeting, as well as analyses and assessments of markets to generate strategic plans for optimal positioning and product success. Duncan’s strong commercialization and marketing background comes from previous roles with Nektar Therapeutics, Zogenix, Amylin, Ligand, Vical and Schering Oncology/Biotech.

“Having worked with Chris previously, I’ve seen first-hand the value he brings to the commercialization process,” said Dan Twibell, Skysis Managing Director. “He is a thoughtful, hands-on professional whose knowledge and expertise will have an immediate impact on our business.”

Duncan is based in San Diego, California.

About Skysis, LLC

Skysis is a team of experienced commercial professionals that provides in-depth strategic insights and commercial execution to biopharmaceutical companies. Through proven processes and an extensive network of subject matter experts, Skysis delivers specialized capabilities in the areas of New Product Planning, Global Pricing & Market Access, Strategic Advisory Services, Market Research and Brand Management. Skysis has more than 85 professionals in the US with a footprint and capabilities that extend across Europe and Asia/Pac. The company’s mission is to partner with its clients to help them achieve a higher level of success.